|
Clinicopathological features
|
N
|
STK31 methylation
|
p
|
|---|
|
+
|
-
|
|---|
|
Age
|
148
| | | |
|
<45
| |
49
|
13
|
0.741
|
|
≥45
| |
66
|
20
| |
|
Histology
|
102
| | | |
|
Squamous cell carcinoma
| |
67
|
13
|
1.000
|
|
Adenocarcinoma
| |
18
|
4
| |
|
Differentiation
|
146
| | | |
|
Well + Moderate
| |
75
|
17
|
0.584
|
|
Poor
| |
42
|
12
| |
|
Lymph node metastasis
|
100
| | | |
|
Positive
| |
23
|
7
|
0.708
|
|
Negative
| |
56
|
14
| |
|
FIGO stage
|
119
| | | |
|
IA1 ~ IIA2
| |
50
|
14
|
0.617
|
|
IIB ~ IIIA
| |
45
|
10
| |
|
Tumor size (cm)
|
148
| | | |
|
<1
| |
40
|
11
|
0.877
|
|
≥1
| |
75
|
22
| |
|
HPV16/18
|
134
| | | |
|
No(HPV-negative)
| |
18
|
0
|
0.037
|
|
Yes
| |
87
|
29
| |
|
HPV genotyping
|
123
| | | |
|
HPV16
| |
81
|
19
|
0.711
|
|
HPV18
| |
20
|
3
| |
|
Squamous cell carcinoma-Ag(SCC-Ag)
|
80
| | | |
|
Normal
| |
24
|
4
|
1.000
|
|
High
| |
45
|
7
| |
|
Neoajuvant Chemotherapy
|
55
| | | |
|
No
| |
23
|
7
|
0.029
|
|
Yes
| |
25
|
0
| |
|
Neoajuvant Chemotherapy resistance
|
55
| | | |
|
No
| |
44
|
9
|
0.037
|
|
Yes
| |
0
|
2
| |
